Astria Therapeutics in the spotlight (part IV)

Locking in >150% profits, upcoming phase 1 expectations, how we're trading, and why...

Since reporting on Astria Therapeutics (ATXS) back in September, the Company expects preliminary results from their Phase 1a trial of STAR-0215 by year-end 2022. The trial aims to establish the prolonged half-life and demonstrate inhibition of plasma kallikrein activity which, if favorable, would provide proof-of-mechanism for STAR-0215 as a potential b…